Analysis of the core functions and clinical application value of Daprodustat in the treatment of anemia

Daprodustat is an oral small molecule drug that is a HIF-PH inhibitor (hypoxia-inducible factor prolyl hydroxylase inhibitor). Its core function is to inhibit HIFprolyl hydroxylase stabilizes the HIF-α subunit, thereby upregulating the level of erythropoietin (EPO) and promoting erythropoiesis. Compared with traditional erythropoietin injections, daporostat regulates endogenous EPO through the oral route, which is closer to physiological regulation, reduces the peak fluctuation of EPO in the blood, and helps maintain hemoglobin stability.

In the treatment of anemia, daprostat is mainly used for the management of anemia related to chronic kidney disease (CKD) and is suitable for dialysis and non-dialysis patients. Clinical studies have shown that daprostat can effectively increase hemoglobin levels and improve anemia symptoms such as fatigue, palpitations and decreased endurance, while reducing the need for traditional erythropoietin dosage and reducing the burden of injections. The convenience of oral administration also improves patient compliance, and is especially suitable for long-term management of patients with CKDanemia.

In terms of safety, daprostat is generally well tolerated, but attention still needs to be paid to cardiovascular risks and the possibility of excessive hemoglobin elevation. In clinical application, it is recommended to regularly monitor hemoglobin, blood pressure and iron metabolism indicators so that the dose can be adjusted according to changes in hemoglobin. In addition, patients with hypertension, heart failure, or a higher risk of blood clots need to pay special attention to cardiovascular safety. Multiple studies have shown that with reasonable dose adjustment, daprostat can improve anemia while keeping the incidence of adverse cardiovascular events under control.

To sum up, daporostat achieves an increase in hemoglobin by regulating the HIF-EPO pathway and is an innovative oral drug in the treatment of anemia related to chronic kidney disease. Its core advantages are oral convenience, good hemoglobin stability and the potential to reduce the need for traditional erythropoietin. Clinically, the rational use of daprostat can effectively improve the symptoms of anemia and improve the quality of life of patients. At the same time, the safety of medication is ensured through standardized monitoring, which reflects its important application value in anemia management.

Keyword tags: Daprostat, HIF-PHinhibitor, anemia in chronic kidney disease, price, generic drugs

Reference materials:https://www.drugs.com/international/daprodustat.html